Current TREATMENT

CURRENT MEDICAL RESPONSE

The only medical response to severe symptomatic Calcific Aortic Stenosis (CAS) is currently a valve replacement, either by open-heart surgery (SAVR) or by a less-invasive procedure called TAVR (Transcatheter Aortic Valve Replacement).  
Unfortunately, not all severe symptomatic CAS patients are eligible for SAVR or TAVR (16%) (1) and some refuse surgery.

1 Durko AP, et al. Annual number of candidates for transcatheter aortic valve implantation per country: current estimates and future projections. European Heart Journal. July 01, 2018; 39(28):2635-2642. (DOI: 10.1093/eurheartj/ehy107)
operation

OPEN HEART SURGERY (SAVR)

The standard treatment consists in replacing the aortic valve with a biological or mechanical prosthesis during open-heart surgery, performed under cardiopulmonary bypass, which temporarily takes over the function of the heart and lungs while the heart is deliberately stopped to allow for a safe and precise valve replacement (1).

 1 The Evolution of Heart Surgery. Electrophysiology and Heart Rhythm Disturbances Team. Lifespan. June 13, 2018.
tavr

TRANSCATHETER AORTIC VALVE REPLACEMENT (TAVR)

Since 2007, a new technique for minimally invasive endovascular surgery called TAVR has been used with spectacular results. This procedure involves replacing the aortic valve via a percutaneous approach, most commonly through the femoral artery (transfemoral route), which provides access to the aortic valve via the arterial system. Other approaches: Transapical (left ventricular apex), Transaortic (via upper mini-sternotomy or right anterior thoracotomy), Transaxillary or subclavian artery, Transcarotid.

OUR SOLUTION: A NON-INVASIVE ULTRASOUND THERAPY

To treat calcific aortic stenosis, Cardiawave has developed a Non-Invasive Ultrasound Therapy (NIUT). NIUT consists in softening the aortic valve, not replacing it. No surgery is required.
Our unique approach could represent both an alternative for patients non eligible for SAVR/TAVR (Surgical Aortic Valve Replacement) and a complementary approach to current procedures to prepare overly calcified aortic valves before the deployment of a TAVR.

TODAY WITH THE CURRENT MEDICAL RESPONSE

  • Patients with no medical response

  • Invasive treatment

  • Length of stay in hospital

  • Valve replacement

  • Risks and Complications, re-hospitalization

  • Overall actual cost: from €50 to €80k (1) (2)

1 Reynolds MR, et al. Cost-effectiveness of transcatheter aortic valve replacement compared with standard care among inoperable patients with severe aortic stenosis: results from the placement of aortic transcatheter valves (PARTNER) trial (Cohort B). American Heart Journal, Circulation. February 03, 2012. (DOI: 10.1161/CIRCULATIONAHA.111.054072)
2 Chevreul K, et al. Cost of transcatheter aortic valve implantation and factors associated with higher hospital stay cost in patients of the FRANCE (French Aortic National CoreValve and Edwards) registry. Cardiovascular Disease. April 24, 2013. (DOI: 10.1016/j.acvd.2013.01.006)

TOMORROW THANKS TO CARDIAWAVE

  • New eligible patients with currently no medical option – Preventive treatment

  • Non-Invasive treatment

  • Ambulatory treatment, short patient length of stay in hospital

  • Softening of native valve

  • Quality of Life improvement, shorter patient recovery time

  • Decrease of cost per procedure